



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

April 2, 2024

Spyre Therapeutics, Inc.  
221 Crescent Street  
Building 23, Suite 105  
Waltham, MA 02456

**Re:   Spyre Therapeutics, Inc.  
      Form S-1, as amended  
      Exhibit Nos. 10.1, 10.2, and 10.5  
      Filed March 27, 2024  
      File No. 333-276251**

Dear Cameron Turtle:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences